UBP selects GE Flexfactory platform to new facility in Hsinchu Industrial park
Ge announced that United BioPharma Inc. (UBP) has selected GE Healthcare’s FlexFactory manufacturing platform for its new facility in Hsinchu Industrial Park, Taiwan focusing on late-stage clinical and commercial production capacity of therapeutic monoclonal antibodies. Taiwanese government support the project to help improve access to biopharmaceuticals.
The new facility, including GE’s FlexFactory based on integrated single-use technologies, will be dedicated to late-stage clinical and commercial production capacity of biopharmaceuticals, especially a monoclonal antibody, UB-421, which will be used for HIV treatment. GE will also continue to work closely with UBP on the establishment of its contract development and manufacturing organization (CDMO) business.
UBP Chairperson, Dr. Chang Yi Wang said that the completion of this state-of-the-art facility equipped with two of GE’s 2,000 litre single-use bioreactors and integrated manufacturing process is a much-anticipated achievement for UBP to enter into commercial-scale current Good Manufacturing Practice (cGMP) -production with international standards. It also resolves the manufacturing bottleneck for UBP’s rich pipeline. With the potential expansion to twelve 2,000-liter production lines within this 8-story building, UBP is and will continue to be the largest protein drug manufacturer in Taiwan in the foreseeable future.